In summary, our data demonstrated that oral treatment with GABA inhibited the HFD-induced obesity and improved glucose intolerance and insulin sensitivity, even after the establishment of obesity and T2DM in mice. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.